Please wait while the formulary information is being retrieved.
ASMANEX (MOMETASONE FUROATE)
- Maintenance therapy for asthma
110 mcg/actuation(30 doses) breath activated inhalr
- Inhale 2 puffs (220 mcg) by inhalation route once daily in the evening
220 mcg/actuation(120 doses) breath activated inhlr
- Inhale 1 puff (220 mcg) by inhalation route once daily at nighttime
220 mcg/actuation(14 doses) breath activated inhalr
- Inhale 1 puff (220 mcg) by inhalation route once daily at nighttime
220 mcg/actuation(30 doses) breath activated inhalr
- Inhale 1 puff (220 mcg) by inhalation route once daily at nighttime
220 mcg/actuation(60 doses) breath activated inhalr
- Inhale 1 puff (220 mcg) by inhalation route once daily at nighttime
Twisthaler 110 mcg/actuation(30 doses) breath activated inhalr
- Inhale 2 puffs (220 mcg) by inhalation route once daily in the evening
Twisthaler 220 mcg/actuation(120 doses) breath activated inhlr
- Inhale 1 puff (220 mcg) by inhalation route once daily at nighttime
Twisthaler 220 mcg/actuation(14 doses) breath activated inhalr
- Inhale 1 puff (220 mcg) by inhalation route once daily at nighttime
Twisthaler 220 mcg/actuation(30 doses) breath activated inhalr
- Inhale 1 puff (220 mcg) by inhalation route once daily at nighttime
Twisthaler 220 mcg/actuation(60 doses) breath activated inhalr
- Inhale 1 puff (220 mcg) by inhalation route once daily at nighttime
Maintenance therapy for asthma
- Inhale 1 puff (220 mcg) by inhalation route 2 times per day
- Inhale 2 puffs (220 mcg) by inhalation route 2 times per day
- Inhale 2 puffs (220 mcg) by inhalation route once daily in the evening
- Inhale 2 puffs (220 mcg) by inhalation route every 12 hours
- Inhale 1 puff (220 mcg) by inhalation route once daily at nighttime
- Inhale 2 puffs (440 mcg) by inhalation route once daily at nighttime
- Inhale 4 puffs (440 mcg) by inhalation route every 12 hours
- Inhale 4 puffs (440 mcg) by inhalation route 2 times per day
- Inhale 2 puffs (440 mcg) by inhalation route 2 times per day
- natalizumab
- Tysabri
Contraindicated
- boceprevir
- elvitegr-cobicist-emtric-tenof
- Incivek
- Kaletra
- Korlym
- lopinavir-ritonavir
- Mifeprex
- mifepristone
- Norvir
- Norvir Soft Gelatin
- ritonavir
- Stribild
- telaprevir
- Victrelis
Severe
Moderate
- amoxicil-clarithromy-lansopraz
- Avelox
- Avelox Abc Pack
- Avelox In Nacl (iso-osmotic)
- Biaxin
- Biaxin Xl
- Biaxin Xl Pak
- Cipro
- Cipro In D5W
- Cipro Xr
- ciprofloxacin
- ciprofloxacin (mixture)
- ciprofloxacin in D5W
- clarithromycin
- Erythrocin
- erythromycin
- erythromycin-sulfisoxazole
- itraconazole
- ketoconazole
- Levaquin
- Levaquin In 5 % Dextrose
- levofloxacin
- levofloxacin in D5W
- moxifloxacin
- moxifloxacin in NaCl (iso-osm)
- norfloxacin
- Noroxin
- ofloxacin
- Omeclamox-pak
- omeprazole-clarith-amoxicillin
- Onmel
- Prevpac
- Sporanox
- Sporanox Pulsepak
- None
Contraindicated
- Fungal infection
- Ocular herpes simplex
- Ocular hypertension
- Osteoporosis
- Parasitic infection
Severe
Moderate
- Active tuberculosis
- Cataracts
- Chickenpox
- Disease of liver
- Glaucoma
- Hypothalamic-pituitary insufficiency
- Immunosuppression
- Measles
- Osteopenia
ASMANEX (MOMETASONE FUROATE)
- Maintenance therapy for asthma
- None
- Allergic rhinitis
- Back pain
- Dysmenorrhea
- Dyspepsia
- Headache disorder
- Musculoskeletal pain
- Oral candidiasis
- Pharyngitis
- Sinusitis
- Upper respiratory infection
More Frequent
Severe
Less Severe
- None
- Acute abdominal pain
- Myalgias
- Nausea
- Oropharyngeal candidiasis
- Urinary tract infection
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anaphylaxis
- Angioedema
- Cataracts
- Glaucoma
- Hypersensitivity drug reaction
- Hypothalamic-pituitary insufficiency
- Immunosuppression
- Infection
- Ocular hypertension
- Osteopenia
- Paradoxical bronchospasm
Less Severe
- Anorexia
- Cough
- Dry throat
- Earache
- Epistaxis
- Fatigue
- Flu-like symptoms
- Gastroenteritis
- Nasal passage irritation
- Pruritus of skin
- Skin rash
- Voice change
- Vomiting
Contraindicated
None
Severe Precaution
Mometasone Inhal Powder
May cause reduced growth rate. Potential HPA-axis suppression. Safety and efficacy not established age < 4 years.
Higher doses increase the risk of growth delay and possible HPA-axis suppression. 110 mcg strength approved ages 4-11 years. Titrate to lowest effective dose. Monitor growth rate.
- 1 Day – 4 Years
- May cause reduced growth rate. Potential HPA-axis suppression. Safety and efficacy not established age < 4 years.
- 4 Years – 12 Years
- May cause reduced growth rate. Potential HPA-axis suppression. Safety and efficacy not established age < 4 years.
Mometasone Inhal Powder (>=200mcg)
May cause reduced growth rate. Potential HPA-axis suppression. Safety and efficacy not established age < 4 years.
Higher doses increase the risk of growth delay and possible HPA-axis suppression. 110 mcg strength approved ages 4-11 years. Titrate to lowest effective dose. Monitor growth rate.
- 1 Day – 4 Years
- Higher doses increase the risk of growth delay and possible HPA-axis suppression. 110 mcg strength approved ages 4-11 years. Titrate to lowest effective dose. Monitor growth rate.
- 4 Years – 12 Years
- Higher doses increase the risk of growth delay and possible HPA-axis suppression. 110 mcg strength approved ages 4-11 years. Titrate to lowest effective dose. Monitor growth rate.
Management or Monitoring Precaution
Mometasone Inhal Powder (<=110mcg)
May cause growth delay. Monitor growth rate and titrate to lowest effective dose.
May reduce growth rate; monitor growth and titrate to lowest effective dose.
- 4 Years – 18 Years
- May cause growth delay. Monitor growth rate and titrate to lowest effective dose.
- 12 Years – 18 Years
- May cause growth delay. Monitor growth rate and titrate to lowest effective dose.
Mometasone Inhal Powder (>=200mcg)
May cause growth delay. Monitor growth rate and titrate to lowest effective dose.
May reduce growth rate; monitor growth and titrate to lowest effective dose.
- 4 Years – 18 Years
- May reduce growth rate; monitor growth and titrate to lowest effective dose.
- 12 Years – 18 Years
- May reduce growth rate; monitor growth and titrate to lowest effective dose.
Mometasone
- Severity Level:
2
- Additional Notes: Acog guidelines rec inhaled corticosteroids for asthma treatment in pregnancy
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Mometasone
Unlikely clinically significant amount excreted with top/nasal administration
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Unlikely clinically significant amount excreted with top/nasal administration |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Maintenance therapy for asthma | |
| J45 | Asthma |
| J45.2 | Mild intermittent asthma |
| J45.20 | Mild intermittent asthma, uncomplicated |
| J45.3 | Mild persistent asthma |
| J45.30 | Mild persistent asthma, uncomplicated |
| J45.4 | Moderate persistent asthma |
| J45.40 | Moderate persistent asthma, uncomplicated |
| J45.5 | Severe persistent asthma |
| J45.50 | Severe persistent asthma, uncomplicated |
| J45.9 | Other and unspecified asthma |
| J45.90 | Unspecified asthma |
| J45.909 | Unspecified asthma, uncomplicated |
| 0-9 | A-Z |
|---|---|
| J45 | Asthma |
| J45.2 | Mild intermittent asthma |
| J45.20 | Mild intermittent asthma, uncomplicated |
| J45.3 | Mild persistent asthma |
| J45.30 | Mild persistent asthma, uncomplicated |
| J45.4 | Moderate persistent asthma |
| J45.40 | Moderate persistent asthma, uncomplicated |
| J45.5 | Severe persistent asthma |
| J45.50 | Severe persistent asthma, uncomplicated |
| J45.9 | Other and unspecified asthma |
| J45.90 | Unspecified asthma |
| J45.909 | Unspecified asthma, uncomplicated |
Formulary Reference Tool